|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophills and regulation by interleukin 10 during intestinal inflammation显示文摘Increasedsecretionofproinflammatorycytokinesbycirculatingpolymorphonuclearneutrophilsandregulationbyinterleukin10duringintes... | S Nikolaus 1, J Bauditz 1, P Gionchetti 2, C Witt 3, H Lochs 1 and S Schreiber 1 1Charité University Hospital, 4th Medical Department, Humboldt University, Berlin, Germany 2Clinica Media I, Policlinico S. Orsola, University of Bolog | 1998 | World Journal of Gastroenterology1998，4，3： | 17 |
| 2 | Osteoclast-like giant cell tumors of the pancreas and liver显示文摘Osteoclast-like giant cell tumors (OGCT) are rare abdominal tumors, which mainly occur in the pancreas. The neoplasms are composed of two distinct cell populations and frequently show an inhomogenous appearance with cystic structures. However, due to the rarity of these tumors, only very limited clinical data are available. Imaging features and sonographic appearance have hardly been characterized. Here we report on two cases of osteoclast-like giant cell tumors, one located within the pancreas, the other within the liver, in which OGCTs are extremely rare. Both patients were investigated by contrast sonography, which demonstrated a complex, partly cystic and strongly vascularized tumor within the head of the pancreas in the first patient and a large, hypervascularized neoplasm with calcifications within the liver in the second patient. The liver OGCT responded well to a combination of carboplatin, etoposide and paclitaxel. With a combination of surgical resection, radiofrequency ablation and chemotherapy, the patient’s survival is currently more than 15 mo, making him the longest survivor with an OGCT of the liver to date. | Juergen Bauditz Birgit Rudolph Wolfram Wermke | 2006 | World Journal of Gastroenterology2006，12，48： | 9 |
| 3 | Angiogenesis and vascular malformations:Antiangiogenic drugs for treatment of gastrointestinal bleeding显示文摘Treatment of gastrointestinal bleeding in patients with angiodysplasias and Osler’s disease (hereditary hemorrhagic teleangiectasia) is clinically challenging. Frequently, vascular malformations occur as multiple disseminated lesions, making local treatment an unfavorable choice or impossible. After local therapy, lesions often recur at other sites of the intestine. However, as there are few therapeutic alternatives, repeated endoscopic coagulations or surgical resections are still performed to prevent recurrent bleeding. Hormonal therapy has been employed for more than 50 years but has recently been shown to be ineffective. Therefore, new therapeutic strategies are required. Understanding of the pathophysiology of angiogenesis and vascular malformations has recently substantially increased. Currently, multiple inhibitors of angiogenesis are under development for treatment of malignant diseases. Experimental and clinical data suggest that antiangiogenic substances, which were originally developed for treatment of malignant diseases, may also represent long-awaited specif ic drugs for the treatment of vascular malformations. However, antiangiogenics display significantly different actions and side-effects. Although antiangiogenics like thalidomide seem to inhibit gastrointestinal bleeding, other substances like bevacizumab can cause mucosal bleeding. Therefore differential and cautious evaluation of this therapeutic strategy is necessary. | Juergen Bauditz Herbert Lochs | 2007 | World Journal of Gastroenterology2007，13，45： | 6 |
| 4 | Effective treatment of gastrointestinal bleeding with thalidomide- Chances and limitations显示文摘For more than 50 years bleeding from gastrointestinal angiodysplasias has been treated by hormonal therapy with estrogens and progesterons. After a randomized study finally demonstrated that hormones have no effect on bleeding events and transfusion requirements, therapy has switched to endoscopic coagulation. However, angiodysplasias tend to recur over months to years and endoscopy often has to be repeated for long time periods. Thalidomide, which caused severe deformities in newborn children in the 1960 s, is now increasingly used after it was shown to suppress tumor necrosis factor alpha, inhibi t angiogenesis and to be also effective for treatment of multiple myeloma. In 2011 thalidomide was proven to be highly effective for treatment of bleeding from gastrointestinal angiodysplasias in a randomized study. Further evidence by uncontrolled studies exists that thalidomide is also useful for treatment of bleeding in hereditary hemorrhagic telangiectasia. In spite of this data, endoscopic therapy remains the treatment of choice in many hospitals, as thalidomide is still notorious for its teratogenicity. However, patients with gastrointestinal bleeding related to angiodysplasias are generally at an age in which women have no child-bearing potential. Teratogenicity is therefore no issue for these elderly patients. Other side-effects of thalidomide like neurotoxicity may limit treatment options but can be monitored safely. | Juergen Bauditz | 2016 | World Journal of Gastroenterology2016，22，11： | 5 |
| 5 | Production of IL-12 in gastritis relates to infection with Helicobacter pylofi 显示文摘 | Bauditz J Ortner M Bierbaum etal | 1999 | Clin Exp hnmunol1999，117，2： | 1 |
| 6 | Production of IL-12 in gastritis relates to infection with Helicobacter pylori显示文摘 | Bauditz J Ortner M Bierbaum M | 1999 | Clin Exp Immunol1999，117，2： | 1 |
| 7 | Thalidomide for treatment of severe intestinal bleeding显示文摘 | Bauditz J Schachschal G Wedel S | | 0，，4： | 1 |
| 8 | Manifesta- tion of thyrotoxic periodic paralysis in two patients with adre- nal adenomas and hyperandrogenaemla 显示文摘 | BIERING H BAUDITZ J PIRLICH M | 2003 | Hormone Re- search2003，59，： | 1 |
| 9 | Long - term follow - up of patients with suprasellar germinomas显示文摘 | Bauditz J Lochs H Ventz M | 2007 | Med Klin(Munich)2007，102，10： | 1 |
| 10 | Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease显示文摘 | Bauditz J Wedel S Lochs H | 2002 | Gu2002，50，2： | 1 |
| 11 | Production of IL-12 in gastritis relates to infection with Helicobacter Pylori 显示文摘 | Bauditz J Ortner M Bierbaum M | 1999 | Clin Exp Immunol1999，117，2： | 1 |
| 12 | Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease显示文摘 | Bauditz J Wedel S Lochs H | | 0，，： | 1 |
| 13 | Sonographie diagnosis of hilar cholangqocarcinomas by the use of contrast agents显示文摘 | Bauditz J Schade T Wermke W | 2007 | Ultraschall Med2007，28，2： | 1 |
| 14 | Results of clinical studies with baytril in claves and pigs显示文摘 | BAUDITZ R | 1987 | REV MED VET1987，，2： | 1 |
| 15 | Sonographic diagnosis of hilar cholangiocarcinomas by the use of contrast agents 显示文摘 | Bauditz J Schade T Wermke W | 2007 | Uhraschall Med2007，28，2： | 1 |
| 16 | Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn' s disease显示文摘 | Bauditz J Wedel S Lochs H | 2002 | Gut2002，50，2： | 1 |
| 17 | Results of clinical studies with Batril in poultry显示文摘 | Bauditz R | 1997 | Vet Med Rev1997，30，2： | 1 |
| 18 | Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease显示文摘 | Bauditz J Wedel S Lochs H | 2002 | Gut2002，50，： | 1 |
| 19 | Production of IL - 12 in gastritis relates to infection with Helicobacter pylori显示文摘 | Bauditz J Ortner M Bierbaum M | 1999 | Clin Exp Immunol1999，117，2： | 1 |
| 20 | Sonographic diagnosis of hilar cholangiocarcinomas by the use of contrast agents显示文摘 | Bauditz J Schade T Werrnke W | 2007 | Ultraschall Med2007，28，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员